One probe to rule them all? new liver scanner tested

NCT ID NCT07400289

Recruiting now Knowledge-focused Sponsor: Echosens Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Aug 06, 2026 · Updated 3 times

Summary

This study is testing a new single probe for FibroScan, a device that measures liver stiffness to assess disease. Researchers want to see if one probe can work as well as the current two-probe system. About 309 adults with chronic liver disease will take part across France and Hong Kong.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: FibroScan device with a single probe
What this could lead to: If successful, this could simplify liver exams by using one probe instead of switching between different sizes.
What could go wrong: This is an early exploratory study focused on measurement accuracy, not treatment. It may not lead to immediate changes in patient care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LIVER DISEASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LIVER DISEASES

Contacts and locations

Locations

CHRU de Besançon
NOT_YET_RECRUITING

Besançon, 25000, France
Hôpital Paris Saclay
NOT_YET_RECRUITING

Orsay, 91400, France
Hôpital St Eloi- CHU Montpellier
NOT_YET_RECRUITING

Montpellier, 34090, France
Prince of Wales Hospital the Chinese University of Hong Kong
RECRUITING

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.